NOVEL RNA THERAPEUTICS AND USES THEREOF

The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BEYER, Thomas Patrick, CHENG, Christine Chih-Tao, EGGEN, Marijean, WILSON, Takako, ANTONELLIS, Patrick Joseph, MILES, Rebecca Ruth, BAWEL, Seth Andrew, WANG, Jibo, LACKNER, Gregory Lawrence
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BEYER, Thomas Patrick
CHENG, Christine Chih-Tao
EGGEN, Marijean
WILSON, Takako
ANTONELLIS, Patrick Joseph
MILES, Rebecca Ruth
BAWEL, Seth Andrew
WANG, Jibo
LACKNER, Gregory Lawrence
description The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression and function, such as dyslipidemia, a cardiovascular disorder, or a cardiometabolic disorder. La présente invention concerne de nouveaux composés thérapeutiques, connus sous le nom d'agents ARNi, qui diminuent l'expression du récepteur ANGPTL8 (exprimé par le gène ANGPTL8), diminuant ainsi l'expression de l'ARNm et l'expression protéique. De tels agents ARNi sont utiles dans le traitement de maladies impliquant la régulation de l'expression et de la fonction d'ANGPTL8, telles que la dyslipidémie, le trouble cardiovasculaire ou le trouble cardiométabolique.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024138111A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024138111A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024138111A13</originalsourceid><addsrcrecordid>eNrjZFD38w9z9VEI8nNUCPFwDXIMcA0N8XQOVnD0c1EIDXYNBou6-rvxMLCmJeYUp_JCaW4GZTfXEGcP3dSC_PjU4oLE5NS81JL4cH8jAyMTQ2MLQ0NDR0Nj4lQBAG9oJKI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NOVEL RNA THERAPEUTICS AND USES THEREOF</title><source>esp@cenet</source><creator>BEYER, Thomas Patrick ; CHENG, Christine Chih-Tao ; EGGEN, Marijean ; WILSON, Takako ; ANTONELLIS, Patrick Joseph ; MILES, Rebecca Ruth ; BAWEL, Seth Andrew ; WANG, Jibo ; LACKNER, Gregory Lawrence</creator><creatorcontrib>BEYER, Thomas Patrick ; CHENG, Christine Chih-Tao ; EGGEN, Marijean ; WILSON, Takako ; ANTONELLIS, Patrick Joseph ; MILES, Rebecca Ruth ; BAWEL, Seth Andrew ; WANG, Jibo ; LACKNER, Gregory Lawrence</creatorcontrib><description>The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression and function, such as dyslipidemia, a cardiovascular disorder, or a cardiometabolic disorder. La présente invention concerne de nouveaux composés thérapeutiques, connus sous le nom d'agents ARNi, qui diminuent l'expression du récepteur ANGPTL8 (exprimé par le gène ANGPTL8), diminuant ainsi l'expression de l'ARNm et l'expression protéique. De tels agents ARNi sont utiles dans le traitement de maladies impliquant la régulation de l'expression et de la fonction d'ANGPTL8, telles que la dyslipidémie, le trouble cardiovasculaire ou le trouble cardiométabolique.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240627&amp;DB=EPODOC&amp;CC=WO&amp;NR=2024138111A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240627&amp;DB=EPODOC&amp;CC=WO&amp;NR=2024138111A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BEYER, Thomas Patrick</creatorcontrib><creatorcontrib>CHENG, Christine Chih-Tao</creatorcontrib><creatorcontrib>EGGEN, Marijean</creatorcontrib><creatorcontrib>WILSON, Takako</creatorcontrib><creatorcontrib>ANTONELLIS, Patrick Joseph</creatorcontrib><creatorcontrib>MILES, Rebecca Ruth</creatorcontrib><creatorcontrib>BAWEL, Seth Andrew</creatorcontrib><creatorcontrib>WANG, Jibo</creatorcontrib><creatorcontrib>LACKNER, Gregory Lawrence</creatorcontrib><title>NOVEL RNA THERAPEUTICS AND USES THEREOF</title><description>The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression and function, such as dyslipidemia, a cardiovascular disorder, or a cardiometabolic disorder. La présente invention concerne de nouveaux composés thérapeutiques, connus sous le nom d'agents ARNi, qui diminuent l'expression du récepteur ANGPTL8 (exprimé par le gène ANGPTL8), diminuant ainsi l'expression de l'ARNm et l'expression protéique. De tels agents ARNi sont utiles dans le traitement de maladies impliquant la régulation de l'expression et de la fonction d'ANGPTL8, telles que la dyslipidémie, le trouble cardiovasculaire ou le trouble cardiométabolique.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFD38w9z9VEI8nNUCPFwDXIMcA0N8XQOVnD0c1EIDXYNBou6-rvxMLCmJeYUp_JCaW4GZTfXEGcP3dSC_PjU4oLE5NS81JL4cH8jAyMTQ2MLQ0NDR0Nj4lQBAG9oJKI</recordid><startdate>20240627</startdate><enddate>20240627</enddate><creator>BEYER, Thomas Patrick</creator><creator>CHENG, Christine Chih-Tao</creator><creator>EGGEN, Marijean</creator><creator>WILSON, Takako</creator><creator>ANTONELLIS, Patrick Joseph</creator><creator>MILES, Rebecca Ruth</creator><creator>BAWEL, Seth Andrew</creator><creator>WANG, Jibo</creator><creator>LACKNER, Gregory Lawrence</creator><scope>EVB</scope></search><sort><creationdate>20240627</creationdate><title>NOVEL RNA THERAPEUTICS AND USES THEREOF</title><author>BEYER, Thomas Patrick ; CHENG, Christine Chih-Tao ; EGGEN, Marijean ; WILSON, Takako ; ANTONELLIS, Patrick Joseph ; MILES, Rebecca Ruth ; BAWEL, Seth Andrew ; WANG, Jibo ; LACKNER, Gregory Lawrence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024138111A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>BEYER, Thomas Patrick</creatorcontrib><creatorcontrib>CHENG, Christine Chih-Tao</creatorcontrib><creatorcontrib>EGGEN, Marijean</creatorcontrib><creatorcontrib>WILSON, Takako</creatorcontrib><creatorcontrib>ANTONELLIS, Patrick Joseph</creatorcontrib><creatorcontrib>MILES, Rebecca Ruth</creatorcontrib><creatorcontrib>BAWEL, Seth Andrew</creatorcontrib><creatorcontrib>WANG, Jibo</creatorcontrib><creatorcontrib>LACKNER, Gregory Lawrence</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BEYER, Thomas Patrick</au><au>CHENG, Christine Chih-Tao</au><au>EGGEN, Marijean</au><au>WILSON, Takako</au><au>ANTONELLIS, Patrick Joseph</au><au>MILES, Rebecca Ruth</au><au>BAWEL, Seth Andrew</au><au>WANG, Jibo</au><au>LACKNER, Gregory Lawrence</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NOVEL RNA THERAPEUTICS AND USES THEREOF</title><date>2024-06-27</date><risdate>2024</risdate><abstract>The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression and function, such as dyslipidemia, a cardiovascular disorder, or a cardiometabolic disorder. La présente invention concerne de nouveaux composés thérapeutiques, connus sous le nom d'agents ARNi, qui diminuent l'expression du récepteur ANGPTL8 (exprimé par le gène ANGPTL8), diminuant ainsi l'expression de l'ARNm et l'expression protéique. De tels agents ARNi sont utiles dans le traitement de maladies impliquant la régulation de l'expression et de la fonction d'ANGPTL8, telles que la dyslipidémie, le trouble cardiovasculaire ou le trouble cardiométabolique.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2024138111A1
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
title NOVEL RNA THERAPEUTICS AND USES THEREOF
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T17%3A40%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BEYER,%20Thomas%20Patrick&rft.date=2024-06-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024138111A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true